Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asian) rheumatoid arthritis patients?

Clinical Rheumatology

Volumn 27, Issue 6, 2008, Pages 787-789

  Ghodke, Yogita ^a   Chopra, Arvind ^b   Joshi, Kalpana ^a   Patwardhan, Bhushan ^a  

^a UNIVERSITY OF PUNE   (India)

^b Center for Rheumatic Diseases   (India)

Author keywords

Gene polymorphism; Indian (Asian); Methotrexate metabolism; Methotrexate response; Pharmacogenetics; Rheumatoid arthritis

Indexed keywords

ADENINE; CYTOSINE; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; THYMIDYLATE SYNTHASE; THYMINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENE DELETION; GENE FREQUENCY; GENETIC LINKAGE; GENOTYPE; HUMAN; INDIAN; LIVER FUNCTION TEST; MOUTH ULCER; NAUSEA; PHARMACOGENETICS; PILOT STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN NODULE; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; HUMANS; INDIA; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 43249121301     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0852-x     Document Type: Article

References (11)

1. O'Dell JR (2005) Methotrexate, leflunamide and combination therapies. In: Harris E Jr, Budd R, Firestein G et al (eds) Kelly's textbook of rheumatology. WB Saunders, Philadelphia, pp 900-19
2. Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism: A promising direction. Pharmacogenomics 3:299-313
3. Ranganathan P, McLeod HL (2006) Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366-1377
4. Dervieux T, Meshkin B, Neri B (2005) Pharmacogenetic testing: Proofs of principles and pharmacoeconomic implications. Mutat Res 573:180-94
5. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-24
6. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215
7. Kumagai K, Hiyama K, Oyama T et al (2003) Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593-600
8. Haagsma CJ, Blom HJ, van Riel PL et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79-84
9. van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:2525-30
10. Urano W, Taniguchi A, Yamanaka H et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12:183-90
11. Berkun Y, Levartovsky D, Rubinow A et al (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227-31